Access Pharmaceuticals

Product Programs

• MuGard
• ProLindac
• Cobalamin mediated oral drug delivery
• Thiarabine
• Cobalamin targeted delivery
• Publications

Scientific Publications

This page contains a partial list of Access Pharmaceuticals' publications, presented either in scientific journals or at major scientific conferences. Due to copyright restrictions, we cannot provide copies of journal articles, but links are provided to the Pubmed abstract of the article. Poster presentations are available for download. Click on the link to the right of the publication to view either the abstract or the poster.

---

 

ProLindac™ (AP5346)

F Joly, A Madroszyk, A Floquet, et al, (2008) AP5346 (ProLindac^TM), a pH-dependent polymer-vectorized DACH platinum, is active in borderline potentially platinum-sensitive ovarian cancer (OC) patients: results from an ongoing Phase I/II trial, Poster presentation at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, held on October 22-26 2008 in Geneva, Switzerland
ProLindac™ Poster Presentation

M Serova, I Bieche, M Broggini, et al, (2008) Role of p21 in sensitivity to DACH-platinum compounds, oxaliplatin and ProLindac^TM, in human cancer cells, Poster presentation at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, held on October 22-26 2008 in Geneva, Switzerland
ProLindac™ Poster Presentation 104

K Rezai, M Serova, E Raymond, et al, (2008) Ex vivo plasma protein binding and in vitro evaluations of AP5346, a novel platinum-bound biopolymer: Evidence showing that =72hr DACH-platinum release may play a major role in cytotoxicity., Poster presentation at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, held on October 22-26 2008 in Geneva, Switzerland
ProLindac™ Poster Presentation 143

P Sood, KB Thurmond, JE Jacob, et al, (2006) Synthesis and Characterization of AP5346, a Novel Polymer-Linked Diaminocyclohexyl Platinum Chemotherapeutic Agent, Bioconjugate Chem., 17, 1270-1279
ProLindac™ Abstract

JR Rice, JL Gerberich, DP Nowotnik, SB Howell (2006) Preclinical Efficacy and Pharmacokinetics of AP5346, A Novel Diaminocyclohexane-PlatinumTumor-Targeting Drug Delivery System, Clin. Cancer Res.,12, 2248-2254.
ProLindac™ Abstract

M Campone, JM Rademaker-Lakhai, J Bennouna, et al (2005) A Phase I and Pharmacokinetic (PK) Trial of AP5346, a Novel Polymer-Linked DACH Platinum (Pt) Compound, Administered as an Intravenous (IV) Infusion Once a Week for 3 Consecutive Weeks in Advanced Solid Tumor Patients. Poster presentation at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, held on November 14 - 18 2005 in Philadelphia, PA.
ProLindac™ Poster Presentation

MuGard™

CM Baud, LE Colon, J Gerberich, DP Nowotnik, SB Howell (2006) Protection from Radiation-Induced Oral Mucositis by MuGard^TM Oral Rinse A Clinical Study and in silico Analysis. Poster presentation at the 18th International MASCC/ISOO Supportive Care in Cancer Symposium,  held on June 22-24 2006 in Toronto, Canada.
MuGard™ Poster Presentation

Cobalamin™ Mediated Tumor Targeting

G Russell-Jones, K McTavish, J McEwan, J Rice, D Nowotnik (2004) Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours.J Inorg Biochem. 98, 1625-33.
Cobalamin™ Mediated Tumor Targeting Abstract

Cobalamin™ Mediated Oral Drug Delivery

KB Chalasani, GJ http://www.ncbi.nlm.nih.gov/pubmed/18990064 Russell-Jones, et al (2007) A novel vitamin B(12)-nanosphere conjugate carrier system for peroral delivery of insulin, J. Control. Release, 117, 421-429.
Cobalamin™ Mediated Oral Drug Delivery Abstract

GJ Russell-Jones (2004) Use of targeting agents to increase uptake and localization of drugs to the intestinal epithelium, J. Drug Target, 12, 113-123.
Cobalamin™ Mediated Oral Drug Delivery Abstract